세계의 아밀로이드증 치료 시장 : 부문별 예측(2025-2030년)

The Amyloidosis Treatment Market was valued at USD 5.23 billion in 2023, expected to reach USD 5.70 billion in 2024, and is projected to grow at a CAGR of 7.57%, to USD 8.73 billion by 2030.

Amyloidosis treatment refers to the strategies and therapies employed to manage amyloidosis, a rare disease characterized by abnormal accumulation of amyloid proteins in organs and tissues. The scope of amyloidosis treatment involves modalities such as medication, stem cell transplantation, and supportive care, each tailored to manage symptoms, slow disease progression, and improve quality of life. The necessity of these treatments is underscored by their ability to target diverse forms of amyloidosis, addressing conditions like AL amyloidosis and ATTR amyloidosis, which can affect organs including the heart, kidneys, liver, and nervous system. Applications of treatment extend from healthcare facilities to home care, with end-use spanning hospitals, specialty clinics, and research institutes. Market growth is influenced significantly by advances in pharmaceutical research, increasing awareness about rare diseases, and improved diagnostic methodologies. Key potential opportunities reside in the development of novel therapeutics and personalized medicine approaches, particularly as recent innovations such as RNA interference-based therapies gain traction. However, the market faces challenges such as high costs of treatment, the complexity of disease management, and the rarity of the condition, which limits broad market expansion. Emerging opportunities for innovation include advancements in genetic research to better understand the disease pathogenesis and the development of more effective biomarkers for early diagnosis and treatment monitoring. Further, the market's nature remains niche yet marked by significant ongoing research and investment, paving the way for new entrants who can bring cost-effective, innovative solutions. Focus areas for innovation include enhancing drug delivery systems, exploring combination therapies, and harnessing artificial intelligence for predictive analytics in treatment outcomes. For optimal business growth, aligning with regulatory pathways to expedite drug approvals and forming strategic partnerships for research and development are recommended, alongside fostering collaborations with healthcare providers to enhance awareness and early diagnosis initiatives.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amyloidosis Treatment Market

The Amyloidosis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Significant prevalence of amyloidosis among rising gigantic population
  • Growing awareness about early diagnosis and amyloidosis treatments
  • Robust research activities to develop novel amyloidosis drugs
• Market Restraints
  • Issues related to high cost and reimbursement policies of amyloidosis treatments
• Market Opportunities
  • Emergence of new treatment options for treating amyloidosis
  • Rising investments to develop modernized healthcare infrastructure
• Market Challenges
  • Complexities and risk associated with amyloidosis treatments

Porter's Five Forces: A Strategic Tool for Navigating the Amyloidosis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amyloidosis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amyloidosis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amyloidosis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amyloidosis Treatment Market

A detailed market share analysis in the Amyloidosis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amyloidosis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amyloidosis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amyloidosis Treatment Market

A strategic analysis of the Amyloidosis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amyloidosis Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acrotech Biopharma, Inc, Alexion Pharmaceuticals, Alnylam Pharmaceuticals Inc., Arcturus Therapeutics, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Attralus, Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Corino Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services Inc, Merck & Co., Inc., Neurimmune AG, Oncopeptides AB, Pfizer Inc., Proclara Biosciences Inc., Prothena Corporation PLC, Regeneron Pharmaceuticals Inc., SOM INNOVATION BIOTECH, SA,, Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Amyloidosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Medication and Surgery. The Medication is further studied across Chemotherapy and Targeted therapy. The Targeted therapy is further studied across Anti-Angiogenesis Therapy, Monoclonal Antibodies, and Proteasome Inhibitors. The Surgery is further studied across Bone Marrow Transplantation/Stem Cell Transplantation and Organ Transplantation.
• Based on End-Users, market is studied across Hospitals and Specialty Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Significant prevalence of amyloidosis among rising gigantic population
    • 5.1.1.2. Growing awareness about early diagnosis and amyloidosis treatments
    • 5.1.1.3. Robust research activities to develop novel amyloidosis drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Issues related to high cost and reimbursement policies of amyloidosis treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of new treatment options for treating amyloidosis
    • 5.1.3.2. Rising investments to develop modernized healthcare infrastructure
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities and risk associated with amyloidosis treatments
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Amyloidosis Treatment Market, by Type

• 6.1. Introduction
• 6.2. Medication
  • 6.2.1. Chemotherapy
  • 6.2.2. Targeted therapy
    • 6.2.2.1. Anti-Angiogenesis Therapy
    • 6.2.2.2. Monoclonal Antibodies
    • 6.2.2.3. Proteasome Inhibitors
• 6.3. Surgery
  • 6.3.1. Bone Marrow Transplantation/Stem Cell Transplantation
  • 6.3.2. Organ Transplantation

7. Amyloidosis Treatment Market, by End-Users

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Specialty Centers

8. Americas Amyloidosis Treatment Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Amyloidosis Treatment Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Amyloidosis Treatment Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie, Inc.
• 2. Acrotech Biopharma, Inc
• 3. Alexion Pharmaceuticals
• 4. Alnylam Pharmaceuticals Inc.
• 5. Arcturus Therapeutics, Inc.
• 6. Astellas Pharma, Inc.
• 7. AstraZeneca PLC
• 8. Attralus, Inc.
• 9. BridgeBio Pharma, Inc.
• 10. Bristol-Myers Squibb Company
• 11. Corino Therapeutics, Inc.
• 12. GlaxoSmithKline PLC
• 13. Ionis Pharmaceuticals, Inc.
• 14. Johnson & Johnson Services Inc
• 15. Merck & Co., Inc.
• 16. Neurimmune AG
• 17. Oncopeptides AB
• 18. Pfizer Inc.
• 19. Proclara Biosciences Inc.
• 20. Prothena Corporation PLC
• 21. Regeneron Pharmaceuticals Inc.
• 22. SOM INNOVATION BIOTECH, SA,
• 23. Sorrento Therapeutics, Inc.
• 24. Spectrum Pharmaceuticals, Inc.
• 25. Takeda Pharmaceutical Company Limited